Review: taking Hydrea and Gleevec together


Summary

Drug interactions are reported among people who take Hydrea and Gleevec together. This review analyzes the effectiveness and drug interactions between Hydrea and Gleevec. It is created by eHealthMe based on reports of 699 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Hydrea

Hydrea has active ingredients of hydroxyurea. It is often used in chronic myeloid leukaemia. (latest outcomes from Hydrea 4,057 users)

Gleevec

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myeloid leukaemia. (latest outcomes from Gleevec 24,566 users)

On Sep, 07, 2016

699 people who take Hydrea, Gleevec are studied.


Number of reports submitted per year:

Hydrea and Gleevec drug interactions.

Drug effectiveness over time:

Hydrea:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)
Gleevec:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Hydrea:
  • female: 100.0% - (1 of 1 people)
  • male: 0.0% - (0 of 0 people)
Gleevec:
  • female: 0.0% - (0 of 1 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Hydrea:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (1 of 1 people)
Gleevec:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • white blood cell count decreased
  • anaemia
  • pyrexia
  • thrombocytopenia
  • dyspnoea
  • platelet count decreased
  • blood lactate dehydrogenase increased
  • haemoglobin decreased
  • nausea
  • pneumonia
1 - 6 months:
  • anaemia
  • haemoglobin decreased
  • fatigue
  • convulsion
  • pleural effusion
  • diarrhoea
  • pericardial effusion
  • platelet count increased
  • ascites
  • decreased appetite
6 - 12 months:
  • ascites
  • convulsion
  • haemoglobin decreased
  • pleurisy
  • atrial fibrillation
  • bradycardia
  • cardiac tamponade
  • electrocardiogram qt prolonged
  • gastrointestinal haemorrhage
  • hepatic ischaemia
1 - 2 years:
  • anaemia
  • ascites
  • haemoglobin decreased
  • pericardial effusion
  • pleural effusion
  • rash
  • interstitial lung disease
  • gastrointestinal haemorrhage
  • oxygen saturation decreased
  • atrial fibrillation
2 - 5 years:
  • neoplasm malignant
  • breast cancer
  • atrial fibrillation
  • pericardial effusion
  • pleural effusion
  • ascites
  • bradycardia
  • cardiac failure
  • cardiac tamponade
  • dyspnoea
5 - 10 years:
  • cardiac failure
  • renal failure acute
  • breast cancer
  • death
  • gastrointestinal haemorrhage
  • haemorrhoidal haemorrhage
  • leukocytosis
  • major depression
  • neoplasm malignant
  • penis carcinoma
10+ years:
  • pancytopenia
not specified:
  • haemoglobin decreased
  • nausea
  • anaemia
  • chronic myeloid leukaemia
  • pyrexia
  • vomiting
  • death
  • rash
  • white blood cell count increased
  • neoplasm malignant

Most common drug interactions by gender *:

female:
  • anaemia
  • nausea
  • haemoglobin decreased
  • vomiting
  • white blood cell count decreased
  • fatigue
  • pyrexia
  • platelet count increased
  • platelet count decreased
  • rash
male:
  • haemoglobin decreased
  • pyrexia
  • chronic myeloid leukaemia
  • blast crisis in myelogenous leukaemia
  • pleural effusion
  • anaemia
  • interstitial lung disease
  • white blood cell count increased
  • drug ineffective
  • thrombocytopenia

Most common drug interactions by age *:

0-1:
  • angina pectoris
  • coronary artery occlusion
  • lipase increased
  • drug exposure during pregnancy
  • premature baby
  • drug withdrawal syndrome neonatal
  • normal newborn
2-9:
  • chloroma
  • abasia
  • arthralgia
  • blast crisis in myelogenous leukaemia
  • capillary leak syndrome
  • chromosome analysis abnormal
  • chronic myeloid leukaemia
  • drug ineffective
  • fall
  • febrile neutropenia
10-19:
  • drug exposure during pregnancy
  • death
  • dyspnoea
  • haemothorax
  • leukostasis
  • osteoarthritis
  • placental disorder
  • premature labour
  • respiratory distress
  • viith nerve paralysis
20-29:
  • nausea
  • vomiting
  • malaise
  • anaemia
  • blood lactate dehydrogenase increased
  • fatigue
  • haemoglobin decreased
  • weight decreased
  • pancytopenia
  • pleural effusion
30-39:
  • white blood cell count increased
  • chronic myeloid leukaemia
  • blast crisis in myelogenous leukaemia
  • haemoglobin decreased
  • nausea
  • platelet count increased
  • face oedema
  • pyrexia
  • death
  • malaise
40-49:
  • pyrexia
  • aspartate aminotransferase increased
  • blast crisis in myelogenous leukaemia
  • thrombocytopenia
  • alanine aminotransferase increased
  • blood lactate dehydrogenase increased
  • headache
  • vomiting
  • chronic myeloid leukaemia
  • splenomegaly
50-59:
  • anaemia
  • rash
  • interstitial lung disease
  • neoplasm malignant
  • chronic myeloid leukaemia
  • pyrexia
  • drug ineffective
  • death
  • gastric antral vascular ectasia
  • neutropenia
60+:
  • haemoglobin decreased
  • anaemia
  • pleural effusion
  • white blood cell count decreased
  • pyrexia
  • platelet count decreased
  • rash
  • thrombocytopenia
  • decreased appetite
  • pericardial effusion

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Hydrea and Gleevec?

Can you answer these questions?

More questions for: Hydrea, Gleevec

You may be interested in these reviews

More reviews for: Hydrea, Gleevec

On eHealthMe, Hydrea (hydroxyurea) is often used to treat chronic myeloid leukaemia. Gleevec (imatinib mesylate) is often used to treat chronic myeloid leukaemia. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.